Presentation is loading. Please wait.

Presentation is loading. Please wait.

HIP1–ALK, A Novel ALK Fusion Variant that Responds to Crizotinib

Published byLucas Lindsey Modified over 5 years ago

Similar presentations

Presentation on theme: "HIP1–ALK, A Novel ALK Fusion Variant that Responds to Crizotinib"— Presentation transcript:

1 HIP1–ALK, A Novel ALK Fusion Variant that Responds to Crizotinib
Douglas D. Fang, PhD, Bin Zhang, PhD, Qingyang Gu, PhD, Maruja Lira, BS, Qiang Xu, PhD, Hongye Sun, PhD, Maoxiang Qian, PhD, Weiqi Sheng, MD, PhD, Mark Ozeck, BS, Zhenxiong Wang, PhD, Cathy Zhang, MS, Xinsheng Chen, MS, Kevin X. Chen, PhD, Jian Li, PhD, Shu-Hui Chen, PhD, James Christensen, PhD, Mao Mao, MD, PhD, Chi-Chung Chan, PhD  Journal of Thoracic Oncology  Volume 9, Issue 3, Pages (March 2014) DOI: /JTO Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Detection of ALK rearrangements and overexpression of the ALK gene in two NSCLC PDX models. A, Quantification of ALK 5′ and 3′ expression levels using the NanoString ALK fusion assay. B, ALK 3′ overexpression in both models as measured by ALK 3′/5′ score in the fusion assay. A background threshold of twofold was denoted by a horizontal dash line (B). C, ALK exon 20 reporter counts detected in NanoString assay. A background threshold of 60 reporter counts was denoted by a horizontal dash line (B). D, Expression levels of ALK in NSCLC PDX models determined by a GeneChip PrimeView human gene expression array or a GeneChip Human Genome U133 Plus 2.0 array in a panel of 22 and seven models, respectively. ALK, anaplastic lymphoma kinase; PDX, patient–derived xenograft; NSCLC, non–small-cell lung cancer. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Identification of a novel HIP1–ALK fusion by RNA-Seq. A, Circos plots depicting ALK rearrangements in LU and LU Chromosomes were drawn to scale around the rim of the circle, and data are plotted on these coordinates. The blue arc and red arc represent intrachromosomal and interchromosomal translocation, respectively. B, Representative aligned reads were shown to map across the exon–exon fusion junction between HIP1 or EML4 and exon 20 of ALK in LU and LU , respectively, as illustrated in the schematic diagram. In LU , the split-reads are shown aligning on the breakpoints of EML4–ALK variant 3a (A) and 3b (B). ALK, anaplastic lymphoma kinase; HIP1, huntingtin interacting protein 1; EML4, echinoderm microtubule-associated protein-like 4. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Validation of ALK rearrangements by RT-PCR and direct sequencing. A, RT-PCR products corresponding to HIP1–ALK and EML4–ALK fusion genes, respectively, in both the primary patient (PA) and PDX tissues. M, DNA ladder. B, Direct sequencing of cDNA revealed fusion junctions of HIP1–ALK and EML4–ALK translocations in LU and LU , respectively. The corresponding locations of the genes were indicated by color-coded bars. C, Schematic representation of HIP1–ALK protein. Regions corresponding to HIP1 and ALK were shown in blue and red, respectively. The fusion protein joins the tyrosine kinase domain of ALK to the TH domain of HIP1. RT-PCR, reverse transcription polymerase chain reaction; ALK, anaplastic lymphoma kinase; HIP1, huntingtin interacting protein 1; EML4, echinoderm microtubule-associated protein-like 4; PA, primary patient; PDX, patient-derived xenograft; TH, talin homology. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 The histology of ALK-rearranged NSCLC patient (PA) and serially passaged PDX tumors and the growth curves of corresponding PDX tumors. The growth characteristics were summarized in the tables on the left. T250 and T500: the number of days required for a tumor to reach 250 mm3 and 500 mm3, respectively. T500-T250: the number of days required for a tumor to grow from 250 mm3 to 500 mm3. PDX, patient-derived xenograft; ALK, anaplastic lymphoma kinase; HIP1, huntingtin interacting protein 1; EML4, echinoderm microtubule-associated protein-like 4; NSCLC, non–small-cell lung cancer. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

6 FIGURE 5 Antitumor activity of crizotinib in ALK wild-type, and HIP1–ALK- and EML4–ALK-rearranged NSCLC PDX models. Crizotinib (by mouth, daily) or cisplatin (by intraperitoneal every week) were administered in tumor-bearing mice for 3 weeks (n=6 or 7 in each group). Data were shown as mean ± standard error of the mean. In both ALK-rearranged models the average tumor volumes in the crizotinib- or cisplatin-treated groups at the endpoint are significantly less than the vehicle control group as determined using one-way analysis of variance. *p < 0.005, **p< 0.01, **p< ALK, anaplastic lymphoma kinase; EML4, echinoderm microtubule-associated protein-like 4; HIP1, huntingtin interacting protein 1; PDX, patient-derived xenograft; NSCLC, non–small-cell lung cancer; WT, wild type. Journal of Thoracic Oncology 2014 9, DOI: ( /JTO ) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "HIP1–ALK, A Novel ALK Fusion Variant that Responds to Crizotinib"

Similar presentations

A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing–Based Circulating Tumor DNA Profiling Exhibits Excellent Response.

A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing–Based Circulating Tumor DNA Profiling Exhibits Excellent Response.
Overexpression of CRM1: A Characteristic Feature in a Transformed Phenotype of Lung Carcinogenesis and a Molecular Target for Lung Cancer Adjuvant Therapy 

Overexpression of CRM1: A Characteristic Feature in a Transformed Phenotype of Lung Carcinogenesis and a Molecular Target for Lung Cancer Adjuvant Therapy 
Volume 204, Issue 1, Pages (January 2011)

Volume 204, Issue 1, Pages (January 2011)
Silencing NKD2 by Promoter Region Hypermethylation Promotes Esophageal Cancer Progression by Activating Wnt Signaling  Baoping Cao, MD, PhD, Weili Yang,

Silencing NKD2 by Promoter Region Hypermethylation Promotes Esophageal Cancer Progression by Activating Wnt Signaling  Baoping Cao, MD, PhD, Weili Yang,
Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer  Lanxi Song, MS, Matthew A. Smith, PhD,

Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer  Lanxi Song, MS, Matthew A. Smith, PhD,
Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK– Positive Human Non–Small Cell Lung Cancer  Kyoung Ho Pyo, PhD, Sun Min Lim,

Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK– Positive Human Non–Small Cell Lung Cancer  Kyoung Ho Pyo, PhD, Sun Min Lim,
WT1 Promotes Invasion of NSCLC via Suppression of CDH1

WT1 Promotes Invasion of NSCLC via Suppression of CDH1
EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients  Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.

EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients  Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.
CDKN2A/p16 Inactivation Mechanisms and Their Relationship to Smoke Exposure and Molecular Features in Non–Small-Cell Lung Cancer  Kit W. Tam, MD, MHS,

CDKN2A/p16 Inactivation Mechanisms and Their Relationship to Smoke Exposure and Molecular Features in Non–Small-Cell Lung Cancer  Kit W. Tam, MD, MHS,
Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.
Detection of Rearrangements and Transcriptional Up-Regulation of ALK in FFPE Lung Cancer Specimens Using a Novel, Sensitive, Quantitative Reverse Transcription.

Detection of Rearrangements and Transcriptional Up-Regulation of ALK in FFPE Lung Cancer Specimens Using a Novel, Sensitive, Quantitative Reverse Transcription.
MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values  Geun Dong Lee, MD, PhD, Seung Eun Lee, MD,

MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values  Geun Dong Lee, MD, PhD, Seung Eun Lee, MD,
A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing–Based Circulating Tumor DNA Profiling Exhibits Excellent Response.

A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing–Based Circulating Tumor DNA Profiling Exhibits Excellent Response.
ITPKA Gene Body Methylation Regulates Gene Expression and Serves as an Early Diagnostic Marker in Lung and Other Cancers  Yi-Wei Wang, PhD, Xiaotu Ma,

ITPKA Gene Body Methylation Regulates Gene Expression and Serves as an Early Diagnostic Marker in Lung and Other Cancers  Yi-Wei Wang, PhD, Xiaotu Ma,
A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer  Maruja E. Lira, Yoon-La Choi, Sun Min Lim, Shibing Deng, Donghui.

A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer  Maruja E. Lira, Yoon-La Choi, Sun Min Lim, Shibing Deng, Donghui.
Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma  Shiyong Li, BS, Yoon-La Choi, MD, PhD, Zhuolin Gong, PhD, Xiao Liu, PhD,

Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma  Shiyong Li, BS, Yoon-La Choi, MD, PhD, Zhuolin Gong, PhD, Xiao Liu, PhD,
Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell.

Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell.
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
TGM2: A Cell Surface Marker in Esophageal Adenocarcinomas

TGM2: A Cell Surface Marker in Esophageal Adenocarcinomas
VAMP2–NRG1 Fusion Gene is a Novel Oncogenic Driver of Non–Small-Cell Lung Adenocarcinoma  Yeonjoo Jung, PhD, Seunghui Yong, BS, Pora Kim, PhD, Hee-Young.

VAMP2–NRG1 Fusion Gene is a Novel Oncogenic Driver of Non–Small-Cell Lung Adenocarcinoma  Yeonjoo Jung, PhD, Seunghui Yong, BS, Pora Kim, PhD, Hee-Young.

Similar presentations

Ads by Google